RGNT

Regentis Biomaterials Ltd.

NYSE: RGNT · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$1.80

+1.12% today

Updated 2026-07-30

Market cap

$12.50M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-24.16

Dividend yield

—

52W range

$1 – $9

Volume

6.5M

Market cap

$12.50M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-24.16

Dividend yield

—

52W range

$1 – $9

Volume

6.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$10.00

+455.56%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-1.38M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-1.45M	$-4.13M	$4.80M	$-13.65M	$-13.65M
EPS	—	—	—	—	$-24.16
Free cash flow	$-1.50M	$-1.22M	$-641000.00	$-1.38M	$-1.38M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RGNT	$12.50M	23	4.3	3.5	5.0	5.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Regentis Biomaterials Ltd. trades at $1.80. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Regentis Biomaterials Ltd.'s stock price?

Regentis Biomaterials Ltd. (RGNT) trades at $1.80.

Is Regentis Biomaterials Ltd. overvalued?

Regentis Biomaterials Ltd. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Regentis Biomaterials Ltd. (RGNT)?

The 12-month analyst consensus target is $10.00, about 455.6% above the current $1.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryMEDICAL INSTRUMENTS & SUPPLIES

CountryUSA

ExchangeNYSE

CurrencyUSD

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$2.87

200D MA$4.04

Shares out0.01B

Float0.00B

Short ratio—

Avg volume6.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RGNT vs LLY →RGNT vs JNJ →RGNT vs ABBV →Stock screener →